Functional analysis of matriptase-2 mutations and domains: Insights into the molecular basis of iron-refractory iron deficiency anemia

American Journal of Physiology - Cell Physiology

Volumn 308, Issue 7, 2015, Pages C539-C547

  McDonald, Cameron J ^a   Ostini, Lesa ^a   Bennett, Nigel ^a   Subramaniam, Nanthakumar ^a   Hooper, John ^b   Velasco, Gloria ^c   Wallace, Daniel F ^a   Nathan Subramaniam, V ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Anemia; Functional analysis; Iron; Localization; Mutation analysis

Indexed keywords

AGRIN; BONE MORPHOGENETIC PROTEIN 6; CHIMERIC PROTEIN; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; ENTEROPEPTIDASE; EPITOPE; HEMOJUVELIN; HEPCIDIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR CLASS A; MATRIPTASE; MATRIPTASE 1; MATRIPTASE 2; PROCOLLAGEN C PROTEINASE; PROTEIN; PROTEIN UEGF; PROTEINASE; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HFE2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SERINE PROTEINASE;

ARTICLE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; GENE; GENE MUTATION; GENETIC VARIABILITY; HEPG2 CELL LINE; HUMAN; IMMUNOFLUORESCENCE TEST; IRON DEFICIENCY ANEMIA; IRON REFRACTORY IRON DEFICIENCY ANEMIA; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ST14 GENE; TMPRSS6 GENE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; SINGLE BLIND PROCEDURE;

ANEMIA, IRON-DEFICIENCY; GPI-LINKED PROTEINS; HEP G2 CELLS; HUMANS; MEMBRANE PROTEINS; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SERINE ENDOPEPTIDASES; SINGLE-BLIND METHOD;

EID: 84926304315     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00264.2014     Document Type: Article

References (31)

1. Altamura S, D’Alessio F, Selle B, Muckenthaler MU. A novel TMPRSS6 mutation that prevents protease auto-activation causes IRIDA. Biochem J 431: 363-371, 2010.
2. Beliveau F, Brule C, Desilets A, Zimmerman B, Laporte SA, Lavoie CL, Leduc R. Essential role of endocytosis of the type II transmembrane serine protease TMPRSS6 in regulating its functionality. J Biol Chem 286: 29035-29043, 2011.
3. Cheng SH, Fang SL, Zabner J, Marshall J, Piraino S, Schiavi SC, Jefferson DM, Welsh MJ, Smith AE. Functional activation of the cystic fibrosis trafficking mutant ΔF508-CFTR by overexpression. Am J Physiol Lung Cell Mol Physiol 268: L615-L624, 1995.
4. Darshan D, Frazer DM, Anderson GJ. Molecular basis of iron-loading disorders. Expert Rev Mol Med 12: e36, 2010.
5. De Falco L, Totaro F, Nai A, Pagani A, Girelli D, Silvestri L, Piscopo C, Campostrini N, Dufour C, Al Manjomi F, Minkov M, Van Vuurden DG, Feliu A, Kattamis A, Camaschella C, Iolascon A. Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA). Hum Mutat 31: E1390-E1405, 2010.
6. Drumm ML, Wilkinson DJ, Smit LS, Worrell RT, Strong TV, Frizzell RA, Dawson DC, Collins FS. Chloride conductance expressed by ΔF508 and other mutant CFTRs in Xenopus oocytes. Science 254: 1797-1799, 1991.
7. Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, Khovananth K, Mudd S, Mann N, Moresco EM, Beutler E, Beutler B. The serine protease TMPRSS6 is required to sense iron deficiency. Science 320: 1088-1092, 2008.
8. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304: 600-602, 2004.
9. Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 40: 569-571, 2008.
10. Folgueras AR, de Lara FM, Pendas AM, Garabaya C, Rodriguez F, Astudillo A, Bernal T, Cabanillas R, Lopez-Otin C, Velasco G. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112: 2539-2545, 2008.
11. Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest 123: 1531-1541, 2013.
12. Hashimoto T, Kato M, Shimomura T, Kitamura N. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J 277: 4888-4900, 2010.
13. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, Quigley JP, Leduc R, Kirchhofer D, Hooper JD. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCδ. J Biol Chem 285: 26162-26173, 2010.
14. Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1 promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252: 368-372, 1998.
15. Inouye K, Tomoishi M, Yasumoto M, Miyake Y, Kojima K, Tsuzuki S, Fushiki T. Roles of CUB and LDL receptor class A domain repeats of a transmembrane serine protease matriptase in its zymogen activation. J Biochem 153: 51-61, 2013.
16. Jiang J, Yang J, Feng P, Zuo B, Dong N, Wu Q, He Y. N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding. J Biol Chem 289: 19500-19507, 2014.
17. Macao B, Johansson DG, Hansson GC, Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 13: 71-76, 2006.
18. Maurer E, Gutschow M, Stirnberg M. Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2. Biochem J 450: 583-593, 2013.
19. McDonald CJ, Jones MK, Wallace DF, Summerville L, Nawaratna S, Subramaniam VN. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PLos One 5: e9594, 2010.
20. McDonald CJ, Wallace DF, Ostini L, Bell SJ, Demediuk B, Subramaniam VN. G80S-linked ferroportin disease: classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective. J Hepatol 54: 538-544, 2011.
21. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41: 478-481, 2009.
22. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093, 2004.
23. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110: 1037-1044, 2002.
24. Ramsay AJ, Quesada V, Sanchez M, Garabaya C, Sarda MP, Baiget M, Remacha A, Velasco G, Lopez-Otin C. Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms. Hum Mol Genet 18: 3673-3683, 2009.
25. Schmidt PJ, Fleming MD. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Hematol Oncol Clin North Am 28: 387-401, 2014.
26. Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/-mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood 121: 1200-1208, 2013.
27. Scott SP, Teh A, Peng C, Lavin MF. One-step site-directed mutagenesis of ATM cDNA in large (20kb) plasmid constructs. Hum Mutat 20: 323, 2002.
28. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8: 502-511, 2008.
29. Szabo R, Hobson JP, List K, Molinolo A, Lin CY, Bugge TH. Potent inhibition and global co-localization implicate the transmembrane Kunitztype serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem 283: 29495-29504, 2008.
30. Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 277: 37637-37646, 2002.
31. Wallace DF, Summerville L, Crampton EM, Subramaniam VN. Defective trafficking and localization of mutated transferrin receptor 2: implications for type 3 hereditary hemochromatosis. Am J Physiol Cell Physiol 294: C383-C390, 2008.